Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in Cytopenia Patients

NCT07081087

Status	RECRUITING
Sponsor	Weizmann Institute of Science
Enrollment	1,500 participants

Key Eligibility Criteria

Inclusion (5)

- Patients aged 18 and up with suspected/confirmed MDS cases referred to BM evaluation either for diagnosis or risk assessment due to cytopenia
- Platelets \< 150 × 10E9/L or
- Absolute neutrophil count \< 1.8 × 10E9/L or
- Hemoglobin (Hgb) \< 13 g/dL (males) and \< 12 g/dL (female) and
- For both sexes, no evidence of Iron, folinic acid, or B12 deficiency

Exclusion (5)

- Women who are pregnant
- Previous diagnosis of leukemia; AML, MPN, ALL, CLL, MGUS/MM or any other gammopathy
- Lymphocytes \> 5000/ul
- Patients who are on disease-related therapy are excluded, unless they are treated with Erythropoietin or Prednisone. See Appendix 2 for the list of excluded treatments.
- Patients who have undergone a bone marrow transplant.

Locations (2 total)

University of California San Diego, San Diego, California, United States
University of Miami, Miami, Florida, United States